oxytetracycline

…2.2 | Trial location and design As Moore-Oxy® (MO; oxytetracycline HCL 5%, Hebei Kexing Pharmaceutical Co. Ltd., Shijiazhuang City, China) was the reference This clinical trial was conducted between the 5th…

illance. MATERIALS AND METHODS Trial location and design This clinical trial was conducted between the 5th of November and the 5th of December 2019 in Ngaoundere II, Ngaoundere III and Martap subdivisions in the Vina Division of the Adamawa plateau. Around 40% of the cattle population of Cameroon is located in the Adamawa region (MINEPIA, 2013). Ngaoundere is the 2 capital of the Adamawa region, with geo-referenced coordinates between 6° 40’ 0” and 7° 30’ 0” north latitude and between 13° 20’ 0” and 14° 10’ 0”’east longitude (Fig. 1). An FMD outbreak in the municipalities of Posted on Authorea 16 Sep 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160029789.93744641 — This a preprint and has not been peer reviewed. Data may be preliminary. Ngaoundere II, Ngaoundere III and Martap was advised to the lead author by a field technician in Ngaoundere on the 4th of November 2019. The following day, the outbreak areas were accessed, and the treatment trials commenced immediately. Two teams of two members each were formed to enable animal treatments and follow-up of the treated cases. Participating farms were selected following demonstration of owner willingness to participate, and included: Horé Mayanga, Borongo, Tchabal Baouro and Mbidjoro. The GPS data of all farms was recorded. As Moore-Oxy® (manufactured in China; MO) was the reference antibiotic commonly used by farmers to manage clinical FMD in the study area, it was decided to compare the efficacy of this formulation on the healing of FMD lesions with that of TS. As MO is administered intra-muscularly and TS is administered topically, on each farm, three animals were matched by age and breed, with similar

…Prophylactic systemic antibiotic treatment was given in the form of an in- tramuscular (IM) injection of 30 mg/kg of long-acting oxytetracycline (ENGEMICINA Animals 2023, 13, 407 D.D., MSD, MSD…

…The intra- assay coefficient of variation (CV) for samples containing 176.5, (oxytetracycline at 10 mg/kg) prior to mulesing. Blood samples 81.9 and 34.8 nmol/L cortisol respectively, were…

…Prophylactic systemic antibiotic treatment was given in the form of an in- tramuscular (IM) injection of 30 mg/kg of long-acting oxytetracycline (ENGEMICINA Animals 2023, 13, 407 D.D., MSD, MSD…

…After castration, a topical antibiotic was administered on the injury area Methods (oxytetracycline; Tenicol spray: MSD) for 5 s. Routine Animals, facilities and experimental design use of an antibiotic spray was used…

e commer­ of orf virus. This was followed by a similar sampling of cial MagMAX™ Pathogen RNA/DNA kit (Thermo Fisher the lesions on days 1 (T1), 3 (T2) and 5 (T3) post- Scientific) and the automated magnetic particle processor treatment of all the lesions observed on the lambs. KingFisher Flex System (Thermo Fisher Scientific), fol­ Samples of 3mL of whole blood were also collected lowing the manufacturer’s instructions. Extracted DNA from the jugular vein through a vacutainer system into samples were stored at −80°C until end of sampling in EDTA tubes to perform haematology in all the animals order to evaluate all of them in a single run of real-time prior to (T0) and ten days (T4) following treatment, PCR quantification. Orf virus detection was performed For personal use only. respectively. using the commercial qPCR kit EXOone Contagious Ecthyma (Exopol, Spain) which targets the BL2 gene Treatment Application that encodes a major envelope viral antigen. The kit con­ Following confirmation of the presence of orf virus in the tains a quantified synthetic positive control, and also an lesions, a single spray of 1.5mL of TS was applied liber­ endogenous control to avoid false-negative results. ally with a spray gun to all orf lesions in Group A lambs, Amplification was performed on a FAST 7500 cycler with the Group B lambs remaining untreated. (Applied Biosystems), and a cut-off value for positive samples was established at cycle quantification (Cq) Clinical Progression values lower than 38. Clinical examination of all lambs was performed by obser­ vers blinded to treatment. This occurred daily for 11 days Virus Culture to determine the clinical progression of the lesions, with Sterile swabs collected at T0, T1, T2 and T3 were submitted data collected on the